A recently published study exploring the association between soluble CA IX and atherosclerotic outcome measures showed that plasma CA IX was detectable in only a small number (14%) of participants and so it was not a meaningful biomarker of cardiovascular disease outcome measures in the CODAM (Cohort On Diabetes and Atherosclerosis Maastricht) cohort [48]. This evidence concerns the gene CA9 and diabetes mellitus.